Elite Pharmaceuticals launches generic methotrexate sodium 2.5 mg tablets

ELITE PHARMACEUTICALS INC /NV/

Product launched for ALL, mycosis fungoides, non-Hodgkin's lymphoma, rheumatoid arthritis, severe psoriasis, pJIA.
Total US market for methotrexate sodium 2.5 mg tablets was ~$63M (12 months ended May 2024, IQVIA).
Marketed under Elite Laboratories, Inc. label; DEA/cGMP facility in Northvale, NJ.
Elite (OTCQB: ELTP) develops and manufactures niche generic products.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.